US20454B1044 - Common Stock
COMPASS THERAPEUTICS INC
NASDAQ:CMPX (5/28/2024, 7:07:32 PM)
After market: 1.53 0 (0%)1.53
+0.06 (+4.08%)
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2020-11-13. The firm is focused on developing proprietary antibody-based therapeutics to treat multiple human diseases. The Company’s pipeline is comprised of three product candidates, such as CTX-009, CTX-471, and CTX-8371. The Company’s lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). The Company’s second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor and its ligand PD-L1, two validated immune-oncology targets.
COMPASS THERAPEUTICS INC
80 Guest Street
Boston MASSACHUSETTS
P: 16175008099
Employees: 26
Website: https://www.compasstherapeutics.com/
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human...
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
CMPX stock results show that Compass Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or...
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
Here you can normally see the latest stock twits on CMPX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: